NovoCure CMO logs RSU vesting and tax share sales

NovoCure Ltd Chief Medical and Innovation Officer Uri Weinberg reported a mix of share grants and mandated sales.

Rhea-AI Filing Summary

NovoCure Ltd Chief Medical and Innovation Officer Uri Weinberg reported a mix of share grants and mandated sales. On February 28, he acquired 12,992 ordinary shares at $0.00 per share from vesting of performance-based restricted stock units. Around these vestings, a total of 10,733 shares were sold in open-market transactions on February 27 and March 2 at weighted average prices of about $13.84 and $13.33 per share to cover tax withholding obligations under NovoCure’s equity plans, described as non-discretionary “sell to cover” trades. After these transactions, Weinberg directly owned 223,477 ordinary shares.

Insider Trade Summary

Net Seller: 10,733 shares

Net Sell 3 txns

Insider Weinberg Uri

Role Chf Medical and Innovation Ofr

Sold 10,733 shs ($147K)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	3,272	$13.3273	$44K
Grant/Award	Ordinary Shares	12,992	$0.00	$0.00
Sale	Ordinary Shares	7,461	$13.8395	$103K

Holdings After Transaction: Ordinary Shares — 223,477 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
2. F2. This transaction was executed in multiple trades at prices ranging from $13.79 USD to $13.91 USD; the price reported above reflects the weighted average sale price.
3. F3. Represents vesting of performance-based restricted stock units.
4. F4. This transaction was executed in multiple trades at prices ranging from $13.31 USD to $13.36 USD; the price reported above reflects the weighted average sale price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NovoCure (NVCR) report for Uri Weinberg?

NovoCure reported that Uri Weinberg received 12,992 ordinary shares from vesting of performance-based RSUs, and sold 10,733 shares in open-market trades to cover tax withholding obligations, leaving him with 223,477 shares held directly.

Were NovoCure (NVCR) insider share sales by Uri Weinberg discretionary trades?

The Form 4 states the 10,733 shares sold were required to cover tax withholding from RSU vesting. The sales were mandated under NovoCure’s equity incentive plan “sell to cover” provisions and are described as non-discretionary for the reporting person.

What prices were reported for Uri Weinberg’s NovoCure (NVCR) share sales?

The filing shows 7,461 shares sold at a weighted average price of about $13.84 and 3,272 shares at about $13.33. Footnotes note each trade was executed in multiple lots within narrow price ranges around those averages.

How many NovoCure (NVCR) shares does Uri Weinberg hold after these transactions?

Following the reported RSU vesting and related tax sales, Uri Weinberg directly holds 223,477 NovoCure ordinary shares. This figure reflects his updated ownership position after both the share award and the two “sell to cover” open-market transactions.

What type of equity award did NovoCure (NVCR) grant to Uri Weinberg?

The Form 4 describes the 12,992-share acquisition as vesting of performance-based restricted stock units. These RSUs converted into ordinary shares at vesting, with associated tax obligations satisfied through mandated open-market share sales.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 04:11 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Weinberg Uri

(Last) (First) (Middle)

C/O NOVOCURE INC.

1550 LIBERTY RIDGE DRIVE, SUITE 115

(Street)

WAYNE PA 19087

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chf Medical and Innovation Ofr

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	02/27/2026		S		7,461(1)	D	$13.8395(2)	213,757	D
Ordinary Shares(3)	02/28/2026		A		12,992	A	$0.00	226,749	D
Ordinary Shares	03/02/2026		S		3,272(1)	D	$13.3273(4)	223,477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. This transaction was executed in multiple trades at prices ranging from $13.79 USD to $13.91 USD; the price reported above reflects the weighted average sale price.

3. Represents vesting of performance-based restricted stock units.

4. This transaction was executed in multiple trades at prices ranging from $13.31 USD to $13.36 USD; the price reported above reflects the weighted average sale price.

Remarks:

	Steven Robbins, as attorney in fact for Weinberg, Uri	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.